Anixa Biosciences Presents Breast Cancer Vaccine Phase 1 Data Showing All Major Endpoints Met
Bitget2026/10/29 23:19- Anixa Biosciences completed its Phase 1 breast cancer vaccine trial, meeting all major endpoints; Phase 2 enrollment is the next milestone.
- Among 35 patients dosed, 74% showed the protocol-specified immune response; no safety concerns were reported.
- Combining the vaccine with Keytruda produced no additional adverse effects, supporting combination use.
- Lira-cel remains in Phase 1 development for ovarian cancer, with periodic data releases tied to enrollment.
- Cash and short-term investments totaled $14 million as of July 31, 2026, with no debt; last fiscal year's cash burn was $7 million.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Morgan Stanley: AI capital expenditure may reach 10 to 15 trillions USD in the next 10 years
Morgan Stanley stated that capital expenditure in the artificial intelligence (AI) sector could reach $10-15 trillions over the next decade.
Morgan Stanley: Apple's target price lowered to $350
Autoliv completes acquisition of MCF Safety Belts
Refining profits surge and oil prices soar; Saudi Aramco Q3 profits grow by 9% and maintains a dividend of 21.9 billions USD.
Driven by rising refining profits and oil prices, Saudi Aramco's third-quarter profits increased by 9%.
Crypto prices
More
